| 1. |
- Bruno, Valentina, 1986-
(författare)
-
Clinical and immunological aspects on recurrent pregnancy loss
- 2020
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Paper I. Effects of low molecular weight heparin on the polarization and cytokine profile of macrophages and T helper cells in vitro. Sci Rep 2018. In paper I low molecular weight heparin (LMWH) in vitro effects on activation and polarization of central regulatory immune cells, such as Th cells and macrophages, were assessed, since LMWH has been widely used as an empiric treatment in recurrent pregnancy loss (RPL) and its immunological effects are not fully known. Isolated blood monocytes and T helper (Th) cells under different activation and polarizing conditions were cultured without or with LMWH at different concentrations. LMWH exposure induced an activated phenotype of macrophages, with high expression of HLA-DR and CD206 assessed by flow cytometry, associated with increased secretion of Th17-associated CCL20, and decreased secretion of CCL2 (M2-associated) and CCL22 (Th2), as measured by multiplex bead array. In accordance, LMWH exposure to Th cells reduced the proportion of CD25highFoxp3+ regulatory Tcells, and intensified IFN-γ secretion. Collectively, a mainly pro-inflammatory effect was noted on two essential tolerance-promoting cells, suggesting that potential immunological effects of LMWH may be effective mainly at an earlier gestational age to provide an appropriate implantation process in women with recurrent miscarriage. Paper II. Low-molecular-weight-heparin increases Th1- and Th17-associated chemokine levels during pregnancy in women with unexplained recurrent pregnancy loss: a randomized controlled trial. Sci Rep 2019.In paper II we investigated whether LMWH could modulate immune responses in vivo during pregnancy of women with unexplained RPL. A Swedish open multi-centre randomized controlled trial included 45 women treated with tinzaparin and 42 untreated women. Longitudinally collected plasma samples were obtained at gestational weeks (gw) 6, 18, 28 and 34 and analyzed by multiplex bead technology for levels of 11 cytokines and chemokines, chosen to represent inflammation and T-helper subset-associated immunity. LMWH-treated and untreated women showed differences during pregnancy of the Th1-associated chemokines CXCL10 (p = 0.01), CXCL11 (p < 0.001) and the Th17- associated chemokine CCL20 (p = 0.04), while CCL2, CCL17, CCL22, CXCL1, CXCL8, CXCL12, CXCL13 and IL-6 did not differ. Significantly higher plasma levels of CXCL10 and CXCL11 in treated women were detected at gw 28 and 34, compared to the untreated ones. Thus, a potential proinflammatory effect, linked mainly to Th1 immunity, was shown, suggesting an unfavorable effect of LMWH treatment, since Th1 responsea are responsible for breaking the fetal-maternal immune tolerance. Paper III. First-trimester trophoblasts obtained by chorionic villus sampling maintain tolerogenic and proteomic features in successful pregnancies despite a history of unexplained recurrent pregnancy loss. Am J Reprod Immunol. 2020.In paper III we investigate the “local” immune changes in women with RPL, since they potentially could reveal important mechanisms in RPL. Supernatants from superfluous chorionic villus sampling material culture was used in an ex vivo model, to determinate the immune proteomics profile and to perform functional assays for M2 like macrophages and regulatory T cells polarization, assessed by flow cytometry technique. Chorionic villi, human fetally derived placental tissue, were shown to induce an M2 like-phenotype and an expansion of Treg cells in an ex vivo model, and these immunological properties were maintained despite a history of RPL. Accordingly, no differences in the inflammation proteomic profile were found in RPL, compared to controls. Trophoblasts in an ex vivo model thus maintain tolerogenic and proteomic profile features in successful pregnancies, despite a history of RPL.
|
|
| 2. |
- Hellberg, Sandra, 1986-
(författare)
-
Effects of Pregnancy and Hormones on T cell Immune Regulation in Multiple Sclerosis
- 2019
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Multiple sclerosis (MS) is characterized by a dysregulated immune system leading to chronic inflammation in the central nervous system. Despite increasing number of treatments, many patients continue to deteriorate. A better understanding of the underlying disease mechanisms involved in driving disease is a pre-requisite for finding new biomarkers and new treatment targets. The improvement of MS during pregnancy, comparable to the beneficial effects of the most effective treatment, suggests that the transient and physiological immune tolerance established during pregnancy could serve as a model for successful immune regulation. Most likely the immune-endocrine alterations that take place during pregnancy to accommodate the presence of the semi-allogenic fetus contribute to the observed disease improvement.The aim of this thesis was to characterize the dysregulated immune system in MS and define potential factors and mechanisms established during pregnancy that could be involved in the pregnancy-induced effects in MS, focusing on CD4+ T cells as one of the main drivers in immunity and in the MS pathogenesis. Using a network-based modular approach based on gene expression profiling, we could show that CD4+ T cells from patients with MS displayed an altered dynamic gene response to activation, in line with a dysregulated immune system in MS. The resulting gene module disclosed cell activation and chemotaxis as central components in the deviating response, results that form a basis for further studies on its modulation during pregnancy. Moreover, a combination of secreted proteins (OPN+CXCL1-3+CXCL10-CCL2), identified from the module, could be used to separate patients and controls, predict disease activity after 2 years and discriminate between high and low responders to treatment, highlighting their potential use as biomarkers for predicting disease activity and response to treatment.The pregnancy hormone progesterone (P4), a potential factor involved in the pregnancy-induced amelioration of MS, was found to significantly dampen CD4+ T cell activation. Further detailed transcriptomic profiling revealed that P4 almost exclusively down-regulated immune-related pathways in activated T cells, several related to or downstream of T cell activation such as JAKSTAT signaling, T cell receptor signaling and cytokine-cytokine receptor interaction. In particular, P4 significantly affected genes of relevance to diseases known to be modulated during pregnancy, where genes associated to MS were most significantly affected, supporting a role for P4 in the pregnancy-induced immunomodulation. By using another approach, the role of thymus in T cell regulation during pregnancy was assessed. Two established measures of thymic output, CD31 expression and TREC content, were used and showed that thymic output of T cells is maintained during human pregnancy, or even possibly increased in terms of regulatory T cells.This thesis further supports a pivotal role for CD4+ T cells and T cell activation in the MS pathogenesis and adds to the knowledge of how they could be involved in driving disease. We identified a novel strategy for capturing central aspects of the deviating response to T cell activation that could be translated into potentially clinically relevant biomarkers. Further, P4 is emerging as a promising candidate for the pregnancy-induced immunomodulation that could be of importance as a future treatment option. Lastly, maintained thymic output of T cells during human pregnancy challenges the rodent-based dogma of an inactive thymus during pregnancy. Thymic dysfunction has been reported not only in MS but also in rheumatoid arthritis, another inflammatory disease that improves during pregnancy, which highlights a potential role for thymus in immune regulation that could be involved in the pregnancy-induced amelioration.
|
|
| 3. |
- Ahlbeck, Lars, 1964-
(författare)
-
Intralymphatic Immunotherapy : A Novel Route to Ameliorate Allergic Rhinitis Due to Pollen
- 2024
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Allergy to pollen and animal dander is a major public health problem. Close to 30% of the population have symptoms from the upper and/or lower respiratory tract when they meet fur animals or pollen. Whereas symptom-relieving medications have a good to sufficient effect on about 80% of those affected, a large group of 10–20% have severe symptoms, despite medication, with an impact on well-being and ability to work. In Sweden, the annual cost of allergy was calculated at €1.3 billion in 2014.Immunotherapy is effective in treating and preventing pollen allergy and allergic asthma, but is expensive, complicated, requiring 40 injections, and takes more than three years to complete if subcutaneous injections are used. Tablets placed under the tongue are another method, with one tablet taken every day for three years. Only 1.5‰ receive such treatment, yet just over 3% would need it.With intralymphatic immunotherapy, a small dose of allergen is given in a lymph node in the groin on 3 occasions, one month apart. As this method takes only eight weeks, it is a much faster and less costly treatment. However, although several studies have shown that the treatment is safe, its efficacy remains the subject of doubt.Our pilot study in 2012, with a 3-year follow-up to 2015, showed encouraging results, and was followed by a double-blind randomised study with 72 participants from 2014 to 2018. The research subjects then received treatment with birch and grass pollen extract or one extract and a placebo. Regardless of treatment, symptoms, quality of life and medication consumption improved during the birch and grass pollen seasons in the 3 years after treatment. Increased frequencies of T-regulatory lymphocytes may explain the non-specific effects.In 2017 to 2018, we conducted a double-blind study with 38 participants, half of whom received placebo and half, active treatment. In this study, we saw no difference between the treatment groups in the first year after treatment. However, after discontinuation and unblinding in 2019, i.e., two years after treatment, the actively treated group improved in terms of symptoms, and quality of life was improved compared with the placebo group despite less need for medication. T-regulatory lymphocytes increased one year after treatment only in the actively treated group.A long-term follow-up of the research subjects from our two larger studies in 2022, i.e., five to eight years after treatment, showed in the double-blind study without a pure placebo that the scores for symptoms, medication use, and quality of life remained as low as after the first three years. In the placebo-controlled study, a statistically significant improvement in symptoms remained during the grass pollen season. Analysing the two studies together, symptom improvement was significant even during the birch pollen season. Thus, although the effect does not seem to diminish, those who did not receive birch, but only grass, needed to use more medication during the birch pollen season in 2022, seven to eight years after treatment. Moreover, those who did not receive grass but only birch needed more medication during the grass pollen season. This may suggest that the non-specific effect begins to wane after seven to eight years.Allergy to pollen is a major problem for individuals and society, where symptom-relieving treatment with drugs is not enough for many. They can be helped with immunotherapy, which takes at least three years, is expensive and fraught with side effects. In contrast, intralymphatic immunotherapy involves three injections over eight weeks. Our three studies show that the treatment is safe and indicate that it has a clinical effect up to eight years after treatment. T-regulatory cells appear to be important to the immunological mechanism, leading to tolerance to pollen.
|
|
| 4. |
- Lindau, Robert, 1989-
(författare)
-
Immune regulation at the foetal-maternal interface; implications for healthy and complicated pregnancies
- 2020
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- For a successful pregnancy, the maternal immune system must acquire tolerance towards the paternal antigens present in the semi-allogeneic foetus. This tolerance is mainly established locally at the foetal-maternal interface, where foetally-derived trophoblasts invade the maternal endometrium (called decidua during pregnancy) and come in close proximity to maternal immune cells. The decidua is populated by maternal immune cells of a unique composition, characterised by their suppressive phenotypes that are essential for maintaining tissue homeostasis. Accordingly, failure of immune tolerance can lead to pregnancy complications. Macrophages and regulatory T-cells are enriched in the decidua and are believed to play important roles in the establishment of tolerance. However, there is limited information regarding the factors that regulate their functions and if their function is compromised in pregnancy complications.The aim of this thesis was to further elucidate which factors are responsible for induction of the regulatory phenotypes of macrophages and T-cells found in the decidua, how tissue resident cells in the decidua contribute to this and if this system is compromised during pregnancy complications, such as preeclampsia and recurrent pregnancy loss.Decidual stromal cells (DSCs) constitute the largest population of tissue resident cells in the decidua. In an in vitro system of macrophage differentiation, we found that Isolated peripheral blood monocytes cultured in conditioned medium (CM) from DSCs acquired a high expression of the regulatory M2 markers CD163, CD209 and CD14, and a low expression of CD86, characteristics of decidual macrophages. This induction was in part mediated by macrophage-colony stimulating factor (M-CSF), as neutralising its effects reduced the expression of CD163. However, since only a partial reduction was reached, other factors are involved. Another likely candidate for this polarisation is interleukin (IL)-34, a second ligand for the M-CSF receptor. We showed that IL-34 is expressed by both DSCs and the foetal placenta. Further, in vitro, IL-34 was able to induce macrophages with similar properties as that of M-CSF-induced macrophages, with high expression of CD163, CD209 and CD14. This was also coupled to a cytokine secretion profile similar to M-CSF-induced macrophages, with high production of IL-10, low production of tumour necrosis factor (TNF) and no production of IL-12. We found no evidence of IL-34 being aberrantly expressed in placentas from preeclamptic women.In addition to promoting induction of macrophages with a regulatory phenotype, CM from DSCs promoted expansion of Foxp3+CD25bright regulatory T (Treg) cells in an in vitro polarisation system, in a SMAD3 dependent manner. Protein profiling of DSCs revealed limited production of the Th2 related IL-13, IL-4, IL-33 and thymic stromal lymphopoietin (TSLP), as well as no production of the Th17 related IL-17A and chemokine (C-C motif) ligand (CCL) 20. Instead we found that DSCs were more prone to production of regulatory factors, such as M-CSF, leukaemia inhibitory factor (LIF) and transforming growth factor (TGF)-β, albeit with addition of the more pro-inflammatory IL-6, chemokine (C-X-C motif) ligand (CXCL) 8 and the Th1-related CXCL10.We also investigated if the placenta´s ability to induce Treg cells and regulatory M2 macrophages is compromised in women with a history of unexplained recurrent pregnancy loss (uRPL) and if the placental secreted protein profile is skewed to a pro-inflammatory response in uRPL. Using surplus materials from chorionic villous sampling (CVS), we generated CM from placental tissue taken from healthy and uRPL pregnancies and used this to polarise macrophages and T-cells in vitro. We found no difference in the ability to induce Treg cells and regulatory M2 macrophages between the healthy group and the uRPL group. Likewise, no differences in the protein profile was observed between the two groups.Taken together, our findings imply that DSCs produce a variety of factors promoting foetal tolerance by induction of Treg cells and regulatory M2 macrophages. Furthermore, we also showed that the placenta retained its ability to induce Treg cells and regulatory M2 macrophages in women with a history of uRPL.
|
|
| 5. |
- Svenvik, Maria, 1973-
(författare)
-
Prediction of Spontaneous Preterm Birth : Clinical and Immunological Aspects
- 2021
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Background: Preterm birth (PTB), defined as birth before 37 weeks of gestation, accounts for most neonatal death and morbidity. Accurate prediction is a pre-requisite for the prevention and proper management of PTB. However, methods for prediction are unsatisfactory, although sonographic cervical length has a moderate predictive value. For clinical utility, adding a biomarker could increase the predictive accuracy. The immune system has an important regulatory role during pregnancy. Thus, presumptive predictive biomarkers may be searched for among immune-related molecules, such as cytokines, chemokines and other inflammation-associated mediators. The aims of this thesis were to identify clinical risk factors and immunological prediction markers for PTB, both in women at increased risk of PTB because of preterm labour (PTL) or preterm prelabour rupture of the membranes (PPROM), and in asymptomatic women in early pregnancy. An additional aim was to explore immune reaction patterns in PTL and PPROM compared to normal pregnancy. Material and methods: In a retrospective registry study, including 20,643 women who delivered during a five-year period, risk factors for Apgar score <7 at five minutes and risk factors for PTB <32 weeks were investigated using univariate and multivariate logistic regression. Furthermore, in a multi-centre mixed case-control and prospective cohort study of women with PTL <34 weeks of gestation (n=80), PPROM (n=40), as well as antenatal controls (n=44) and controls in labour at term (n=40), plasma levels of cytokines and chemokines representing different types of immune responses were analysed with a multiplex bead assay. In addition, an extended protein analysis exploring 92 inflammation-associated plasma proteins using proximity extension assay (PEA) was performed, as well as analysis of 67 different oxylipins by liquid chromatography coupled to tandem mass spectrometry. Finally, the PEA technique was used also to explore plasma proteins in a case-control study including 46 women with PTB and 46 women with normal pregnancies and delivery at term. Results and conclusions: A number of partly preventable clinical risk factors for PTB <32 weeks were identified, for example smoking (odds ratio (OR) 1.61 (95% confidence interval (CI) 1.07-2.41)); preeclampsia (OR 5.48 (95% CI 3.39-8.86)); and multiple gestation (OR 15 (95% CI 10-24)). The most evident risk factor for low Apgar scores was PTB; the more preterm the higher the risk. This provides important information for health care professionals, and offers motivations for preventive strategies regarding smoking cessation. Both PTL and PPROM were associated with a more pro-inflammatory profile compared to antenatal controls, with an increase in CXCL1. In addition, PTL showed higher CCL17 levels, and PPROM showed higher IL-6 levels compared with normal pregnancy. The inflammatory profile was even higher in labour at term, reflected by higher levels of CXCL1, CXCL8, and IL-6 compared with PTL, probably due to the more advanced stage of the parturition process in these women. To identify women with PTL and subsequent PTB <34 weeks of gestation, we found that a combination of the proteins IL-6, IL-17C, IL-10RB, and FGF-23 strongly correlated with PTB <34 weeks with an area under the curve (AUC) of 0.90; inferring a sensitivity of 90%, and specificity of 74%. For the prediction of delivery within 48 hours in women with PTL, the combination of IL-6 and IL-17C displayed an AUC of 0.88, with a sensitivity of 100%, and a specificity of 71%. Additionally, plasma levels of oxylipins were associated with time of birth. Lower levels of 9,10-DiHODE were associated with PTB <34 weeks (adjusted (a) OR 0.12 (0.024-0.62)) and with delivery within 48 hours (aOR 0.13 (0.019-0.93)), while higher levels of 11,12-DiHETre were associated with delivery <34 weeks (aOR 6.19 (1.17-32.7)) and higher levels of 8-HETE were associated with delivery within 48 hours (aOR 5.01 (1.13-22.14)). In asymptomatic women, plasma levels of combinations of inflammation-associated proteins in the first and the second trimester also revealed predictive information regarding subsequent risk for PTB <34 weeks. Combining MMP10trim1, sCD40trim2, MCSFtrim2, Flt3Ltrim2, and FGF-21diff (diff= difference in protein levels comparing the first and second trimesters) provided a prediction model with an AUC of 0.90. Proteins from the first trimester exclusively (sCD40 and MMP10) rendered an AUC of 0.76. This work provides valuable knowledge in the field of PTB and PTL with useful information on risk factors for PTB. Important associations between levels of inflammation-associated proteins and oxylipins with PTB following PTL were found. Before these findings can have clinical implications, they need to be validated in other cohorts. Additionally, in order to be clinically useful as a prediction tool for PTB, a bedside test is needed. Since the PEA technique is PCR-based, this might be achievable. For prediction of PTB in early pregnancy, we have interesting findings with acceptable accuracy based on samples from both the first and the second trimesters. However, as preventive interventions for PTB are preferably initiated early in pregnancy, a prediction tool has better value if it is based on plasma samples from the first trimester. Therefore, we plan to extend this study and evaluate other potential protein biomarkers.
|
|
| 6. |
- Bensberg, Maike, 1993-
(författare)
-
DNA methylation in T cell leukaemia
- 2024
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- T cell acute lymphoblastic leukaemia (T-ALL) is a predominantly paediatric cancer that stems from malignant transformation of developing T cells. While the disease has an overall survival rate of 80%, the intense chemotherapy treatment causes severe toxicity and long-term side effects. Furthermore, the survival rate for patients in relapse is less than 25%. Consequently, there is a need for improved therapy options to reduce treatment-related side effects and improve the survival rate of relapsed patients. Targeting aberrant DNA methylation with hypomethylating agents (HMAs) has been successful in the treatment of myelodysplastic syndromes and acute myeloid leukaemia but has not been routinely used in the treatment of T-ALL, despite DNA hypomethylation being observed in T-ALL patients. In this work, we employed a comprehensive set of molecular and sequencing-based techniques to explore the possibilities of HMAs as a treatment option for T-ALL.We made the discovery that the DNA demethylating enzyme ten-eleven translocation 2, TET2, is downregulated or completely silenced in primary T-ALL. Moreover, the TET2 promoter was highly methylated in a group of patients, suggesting that TET2 itself can be silenced through DNA methylation in T-ALL. By treatment with HMAs, TET2 was demethylated in T-ALL cell lines and was one of few genes that was activated upon loss of DNA methylation, indicating that TET2 expression is regulated by DNA methylation in T-ALL cell lines. The development of a novel HMA, the DNMT1-specific inhibitor GSK-3685032, offers a tool to reveal the mechanism of action of the traditional HMAs, 5- azacytidine and decitabine, and to study the effects of acute loss of DNA methylation on cancer cells. We found that 5-azacytidine and decitabine are cytotoxic to T-ALL cells primarily by creating DNA double strand breaks. In contrast, GSK did not prompt a DNA damage response and instead reduced global DNA methylation to as little as 18% with limited cytotoxicity only occurring after levels of DNA methylation had dropped below 30%, a level of demethylation not achieved with DEC or AZA.T-ALL is more than two times more common in boys than girls and mutations in X-linked tumour suppressor genes that escape X inactivation, have been suggested as an underlying cause for the observed sex-bias. In theory, these aberrations would be more detrimental in XYmale cells than in XX-female cells due to the presence of an extra protective copy of the gene in females. We profiled DNA methylation during T cell development and created a map of sex-specific gene expression and expression from the inactive X chromosome, finding that some, but not all, suggested tumour suppressor genes in fact escape X inactivation. These results highlight the importance of profiling the healthy cells that T-ALL arises from to correctly judge the functional impact of gene dysregulation in cancer.In the last study, we aimed to investigate the role of N6-adenine methylation (6mdA) during T cell differentiation. While 6mdA is common in bacteria it is much rarer in humans. Nevertheless, 6mdA has previously been associated with several cellular processes, including cancer progression. Our study calls the presence of 6mdA in mammals into question by exposing limitations of the techniques used in its analysis. We show that contamination with bacterial DNA or 6mAcontaining RNA, nonspecific antibody binding, and low precision of third-generation sequencing techniques all hinder the detection and investigation of rare DNA modifications, such as 6mdA.Together, this work is an in-depth study of the function and the potential of DNA methylation in the biology of healthy and malignant T cells.
|
|
| 7. |
- Huoman, Johanna, 1987-
(författare)
-
Immune maturation and modulation in childhood allergies : Aspects of epigenetic, mucosal and systemic immune mediators in allergy development and prevention
- 2020
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The prevalence of allergic diseases has in the past century increased among children in affluent societies. Underlying causes are incompletely disentangled, but decreased diversity in environmental and microbial exposures could drive allergy development. Allergic individuals possess imbalanced immune responses, skewed in favour of Th2 cells along with lesser Th1 and Treg responses. As allergy development early in life increases the risk of developing further allergic manifestations later, early prevention is key. Thus, interventions in pregnancy, early life and childhood may modulate immunity towards tolerance, although underpinnings of immune maturation and modulation in allergy prevention throughout childhood are not entirely understood. In this thesis, these questions are addressed in children with a high propensity of developing allergic disease or who already have manifested allergies.Chemokines are crucial for immune cell recruitment to the allergic reaction site, and associate with allergy development in childhood. In Paper I, circulating levels of the allergy-related chemokines CCL17, CCL18, CCL22, CXCL10 and CXCL11 were studied in the natural course of allergic disease. Elevated levels of the Th2/Treg-regulated chemokine CCL18 in infancy and childhood associated with development of asthma and/or sensitisation. Moreover, this finding conferred higher odds of developing asthma and sensitisation from early school age until adolescence. Additionally, increased levels of the Th1-associated chemokines CXCL10 after birth, and decreased levels of CXCL11 at birth, preceded asthma development later in life. Hence, Paper I showed that circulating chemokine levels in different ways precede allergy development.Epigenetic modifications, such as DNA methylation, comprise a link between the genetic setup and environmental exposures, and regulate processes such as Th cell differentiation. Perinatal treatment with Lactobacillus reuteri and ω-3 fatty acids prevent development of some IgE-mediated manifestations. However, the drivers of the immunostimulating and pro-resolving effects of these treatments are sparsely examined. In Papers II and III, epigenome-wide DNA methylation patterns in CD4+ cells upon pre-and postnatal L. reuteri supplementation alone or in combination with ω-3 fatty acids were studied. In Paper II, the greatest epigenome wide differential methylation was evident at birth, mainly directed towards hypomethylation, indicating transcriptional availability of affected genes. Network analyses revealed several immune related pathways, and a relationship of differentially methylated genes to allergy development. Thus, prenatal L. reuteri treatment seemingly poises Th cells towards immune activation at birth, possibly influencing immune maturation as well as allergy development in the child.In Paper III, epigenome-wide DNA methylation patterns were surveyed at birth. In this on-going trial, mothers are treated during the latter half of pregnancy with a combination of L. reuteri and ω-3 fatty acids. Four different treatment groups were studied, and the largest differential methylation was seen in the double active treatment group. In contrast to Paper II, most CpGs and genes were hypermethylated, indicating repressed gene transcription. In line with Paper II, network analyses showed that T cell and immune mediated pathways were affected by treatment, and synergistic effects of the double treatment were indicated. Taken together, prenatal treatment with L. reuteri and/or ω-3 fatty acids altered the epigenome to different extents at birth, mainly towards hypermethylation, and often affected immune related pathways.Immunomodulatory effects of sublingual immunotherapy in children and adolescents are scarcely investigated. In Paper IV, circulating and salivary immune mediators were investigated in timothy grass-pollen allergic children treated with sublingual immunotherapy. Actively treated children had elevated levels of timothy grass pollen-specific IgA antibodies in saliva, along with increased circulating levels of the Th1-associated chemokines CXCL10 and CXCL11, both after treatment ending and two years later. Taken together, sublingual immunotherapy modulates local and peripheral immune responses in children with timothy grass pollen-induced allergy, by augmenting Th1-responses, lessening Th2-responses and inducing immunomodulatory responses, suggesting induction of tolerance, also partly in the long-term.Altogether, the studies in this thesis have shown altered immune regulation in children developing allergies. Moreover, immunomodulatory effects of prenatal treatment with probiotics and ω-3 fatty acids, and sublingual immunotherapy in children with grass pollen-induced allergic disease, were revealed. DNA methylation patterns and immunologic mediators in blood and saliva could potentially serve as appropriate biomarkers for allergic disease. Long term health benefits can be reached by intervening early in life, and further knowledge about the mechanisms behind this could promote the prevention of allergic diseases and hence improve the quality of life for children and adolescents.
|
|
| 8. |
- Lizano Fallas, Verónica, 1985-
(författare)
-
Toxicoproteomics, from finding molecular targets to evaluating the impact on human health
- 2023
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The exposome refers to all exposures, including exposures to chemicals, that an individual may encounter over the whole life, from conception to death, that influence the individual’s health. To date, over 200,000 chemicals have been registered under the legislative framework of the European Union. Exposomics studies have revealed that individuals are exposed to chemical mixtures consisting of hundreds of compounds simultaneously. The risks to human health posed by many of these chemicals and chemical mixtures are still unknown and require evaluation. Traditional methods for assessing chemicals and chemical mixtures have been inadequate in addressing the increasing number of potentially toxic compounds in the environment. Current high-throughput toxicology methods, which involve the application of batteries of in vitro bioassays, can reduce the time and costs of analysis. However, these methods evaluate the impact on well-established pathways that have already been identified as being affected by exposure, making it difficult to discover new modes of action. The goal of this thesis is to provide a method to unravel the targets of chemicals for a better understanding of the mechanisms of action of chemicals and chemical mixtures under the scenario of the exposome. The proteome integral solubility alteration (PISA) assay is a proteome-wide approach for drug-target identification. However, implementing the PISA assay to address toxicological challenges requires different experimental considerations from chemical properties and toxicology principles. Moreover, it is necessary to translate the data from target identification to an understanding of the potential impact on human health. Therefore, three steps were followed to implement the PISA method in the field of toxicology: i) experimental considerations of the method for toxicology and chemical assessment purposes, ii) analysis of the method capability in the field of toxicology, and iii) development of pipelines from the target identification to the understanding of potential impact on human health. The results showed the capability of the PISA assay to identify the protein targets of single chemicals and chemical mixtures, extending, in an unbiased manner, the list of evaluated biological pathways in current available methodologies. The approach presented here reduces the time and cost associated with experimental and data analysis work, which could aid in the chemical risk assessment process in the context of the exposome.
|
|
| 9. |
- Forsberg, Anna, 1985-
(författare)
-
Immunomodulatory effects of probiotic supplementation during pregnancy and infancy in allergy prevention studies
- 2017
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The incidence of allergic diseases is increasing, possibly due to a reduced intensity and diversity of microbial stimulation. More knowledge is needed on the immunological mechanisms underlying the eczema preventive effect of pre- and postnatal probiotic supplementation. The pregnancy period seems to be of essential importance, since both epidemiological and experimental animal studies show the importance of microbial exposure during gestation on allergy prevention.We have performed a study where the probiotic lactic acid producing bacteria Lactobacillus reuteri was supplemented to pregnant women, at risk of having an allergic infant. The pregnant mothers received the study product from gestational week 36 until delivery, and the infants then continued with the same product until one year of age. The probiotic, as compared with placebo, supplemented infants had less IgE-associated eczema at two years of age.In order to investigate how the supplementation affected the immune system peripheral blood was collected and immune cells were stimulated with common allergens and TLR ligands. The probiotic treated group responded with a more regulated response to allergens and TLR2 ligands in comparison to the placebo supplemented group. We also investigated how the probiotic supplementation affected the epigenetic methylation pattern in circulating T helper cells during infancy, observing the most pronounced effects at birth.In a follow up study, supplementation was started earlier to possibly gain a stronger allergy preventive effect via changes in maternal immune regulation. Supplementation with Lactobacillus reuteri and ω-3 fatty acids started at gestational week 20 and throughout pregnancy. After 20 weeks of supplementation, some immunomodulatory effects among circulating activated regulatory T cells and a subpopulation of monocytes were noted. Several systemic immune modifying effects of pregnancy were observed.In summary, probiotics show several immunomodulatory effects in infants and pregnant women. However, more research is needed to better understand the effects of the probiotic supplementation to aid future identification of more efficacious allergy preventive strategies.
|
|
| 10. |
- Humbert, Marion, et al.
(författare)
-
Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age
- 2023
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : National Academy of Sciences. - 0027-8424 .- 1091-6490. ; 120:12
-
Tidskriftsartikel (refereegranskat)abstract
- Pre-existing SARS-CoV-2-reactive T cells have been identified in SARS-CoV-2-unexposed individuals, potentially modulating COVID-19 and vaccination outcomes. Here, we provide evidence that functional cross-reactive memory CD4+ T cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is established in early childhood, mirroring early seroconversion with seasonal human coronavirus OC43. Humoral and cellular immune responses against OC43 and SARS-CoV-2 were assessed in SARS-CoV-2-unexposed children (paired samples at age two and six) and adults (age 26 to 83). Pre-existing SARS-CoV-2-reactive CD4+ T cell responses targeting spike, nucleocapsid, and membrane were closely linked to the frequency of OC43-specific memory CD4+ T cells in childhood. The functional quality of the cross-reactive memory CD4+ T cell responses targeting SARS-CoV-2 spike, but not nucleocapsid, paralleled OC43-specific T cell responses. OC43-specific antibodies were prevalent already at age two. However, they did not increase further with age, contrasting with the antibody magnitudes against HKU1 (β-coronavirus), 229E and NL63 (α-coronaviruses), rhinovirus, Epstein–Barr virus (EBV), and influenza virus, which increased after age two. The quality of the memory CD4+ T cell responses peaked at age six and subsequently declined with age, with diminished expression of interferon (IFN)-γ, interleukin (IL)-2, tumor necrosis factor (TNF), and CD38 in late adulthood. Age-dependent qualitative differences in the pre-existing SARS-CoV-2-reactive T cell responses may reflect the ability of the host to control coronavirus infections and respond to vaccination. Copyright © 2023 the Author(s).
|
|
